- Home
- SGMT vs MIST Comparison
SGMT vs MIST Comparison
Compare SGMT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | MIST |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 176.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SGMT | MIST |
|---|---|---|
| Price | $4.90 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $26.38 | $8.50 |
| AVG Volume (30 Days) | 321.0K | ★ 1.8M |
| Earning Date | 03-11-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | $1,653.36 |
| Revenue Next Year | N/A | $12.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $0.63 |
| 52 Week High | $11.41 | $3.06 |
Technical Indicators
Market Signals| Indicator | SGMT | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 24.45 |
| Support Level | N/A | N/A |
| Resistance Level | $6.62 | $2.01 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 25.74 | 0.00 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).